60 results
424B5
WINT
Windtree Therapeutics Inc
9 Nov 23
Prospectus supplement for primary offering
4:11pm
, we initiated a Phase 2 global clinical study, or the SEISMiC Study, to evaluate istaroxime for the treatment of early cardiogenic shock (Society … at the European Society of Cardiology Heart Failure Meeting in Madrid, Spain and, in September 2022, the results were published in the European
424B4
dll41
20 Apr 23
Prospectus supplement with pricing info
6:03pm
8-K
EX-99.1
xqmhl5 atejucp
14 Nov 22
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
7:33am
8-K
EX-99.1
096 fu6hothkbk
11 Aug 22
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
4:06pm
8-K
EX-99.1
jxfpc2f 0e
23 May 22
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
4:01pm
8-K
k880by6u4qs
23 May 22
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
4:01pm